SANUWAVE Health (SNWV) 10-Q13 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
Document And Entity Information	Mar. 31, 2014	11-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'SANUWAVE Health, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	46,966,519
Amendment Flag	'false	'
Entity Central Index Key	'0001417663	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
CURRENT ASSETS	'	'
Cash and cash equivalents	$7,231,946	$182,315
Accounts receivable - trade, net of allowance for doubtful accounts of $46,030 in 2014 and $43,282 in 2013	61,661	139,736
Inventory	250,484	246,006
Prepaid expenses	153,908	75,020
TOTAL CURRENT ASSETS	7,697,999	643,077
PROPERTY AND EQUIPMENT, at cost, less accumulated depreciation (Note 3)	10,497	13,267
OTHER ASSETS	11,457	11,444
INTANGIBLE ASSETS, at cost, less accumulated amortization (Note 4)	843,580	920,269
TOTAL ASSETS	8,563,533	1,588,057
CURRENT LIABILITIES	'	'
Accounts payable	563,799	935,028
Accrued expenses (Note 5)	635,163	863,572
Accrued employee compensation	197,304	140,102
Convertible promissory note (Note 9)	'	147,775
Promissory notes	'	89,038
Interest payable, related parties (Note 7)	80,072	163,729
Capital lease payable	2,659	3,951
TOTAL CURRENT LIABILITIES	1,478,997	2,343,195
NON-CURRENT LIABILITIES	'	'
Notes payable, related parties (Note 7)	5,372,743	5,372,743
TOTAL LIABILITIES	6,851,740	7,715,938
STOCKHOLDERS' EQUITY (DEFICIT)	'	'
PREFERRED STOCK, SERIES A CONVERTIBLE, par value $0.001, 6,175 shares issued and outstanding (Note 10)	6	'
COMMON STOCK, par value $0.001, 150,000,000 shares authorized; 46,846,519 and 37,984,182 issued and outstanding in 2014 and 2013, respectively	46,847	37,984
ADDITIONAL PAID-IN CAPITAL	86,433,681	76,037,490
ACCUMULATED OTHER COMPREHENSIVE INCOME	5,256	6,688
ACCUMULATED DEFICIT	-84,773,997	-82,210,043
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	1,711,793	-6,127,881
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$8,563,533	$1,588,057

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accounts Receivable, Allowance for Doubtful Accounts (in Dollars)	$46,030	$43,282
Preferred shares par value (in Dollars per share)	$0.00	$0.00
Preferred shares issued	0	0
Preferred shares outstanding	0	0
Preferred stock, shares authorized	4,993,825	5,000,000
Common stock par value (in Dollars per share)	$0.00	$0.00
Common Stock, shares authorized	150,000,000	150,000,000
Common Stock, shares issued	46,846,519	37,984,182
Common Stock, shares outstanding	46,846,519	37,984,182
Convertible Preferred Stock [Member]	'	'
Preferred shares par value (in Dollars per share)	$0.00	'
Preferred shares issued	6,175	'
Preferred shares outstanding	6,175	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
REVENUE	$145,098	$201,234
COST OF REVENUE	18,337	55,811
GROSS PROFIT	126,761	145,423
OPERATING EXPENSES	'	'
Research and development	764,845	344,685
General and administrative	1,300,311	851,921
Depreciation	4,715	4,991
Amortization	76,689	76,689
TOTAL OPERATING EXPENSES	2,146,560	1,278,286
OPERATING LOSS	-2,019,799	-1,132,863
OTHER INCOME (EXPENSE)	'	'
Loss on embedded conversion feature of Senior Secured Notes (Note 6)	'	-3,737,000
Interest expense, net	-542,292	-508,890
Gain on sale of fixed assets	'	7,500
Gain/(loss) on foreign currency exchange	-1,863	1,920
TOTAL OTHER INCOME (EXPENSE)	-544,155	-4,236,470
LOSS BEFORE INCOME TAXES	-2,563,954	-5,369,333
INCOME TAX EXPENSE	0	0
NET LOSS	-2,563,954	-5,369,333
OTHER COMPREHENSIVE INCOME (LOSS)	'	'
Foreign currency translation adjustments	-1,432	-6,925
TOTAL COMPREHENSIVE LOSS	($2,565,386)	($5,376,258)
LOSS PER SHARE:	'	'
Net loss - basic and diluted (in Dollars per share)	($0.06)	($0.25)
Weighted average shares outstanding - basic and diluted (in Shares)	39,646,922	21,278,128

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
Consolidated Statements of Cash Flows (Unaudited) (USD $)	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($2,563,954)	($5,369,333)
Adjustments to reconcile net loss to net cash used by operating activities	'	'
Amortization	76,689	76,689
Depreciation	4,715	4,991
Change in allowance for doubtful accounts	2,748	5,976
Stock-based compensation - employees, directors and advisors	70,778	317,601
Stock issued for consulting services	597,150	186,200
Gain on sale of property and equipment	'	-7,500
Changes in assets - (increase)/decrease	'	'
Accounts receivable - trade	75,327	-11,611
Inventory	-4,478	31,383
Prepaid expenses	-78,888	12,089
Other	-13	125
Changes in liabilities - increase/(decrease)	'	'
Accounts payable	-371,229	-196,869
Accrued employee compensation	57,202	-158,484
Accrued expenses	-228,409	-98,605
Promissory notes - accrued interest	-21,813	'
Interest payable	-83,657	-1,793
NET CASH USED BY OPERATING ACTIVITIES	-2,120,800	-1,043,674
Accrued interest on 18% Convertible Promissory Notes	7,168	'
Loss on embedded conversion feature of Senior Secured Notes	'	3,737,000
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Sale of property and equipment	'	7,500
Purchase of property and equipment	-1,945	'
NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES	-1,945	7,500
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from 2014 Private Placement, net	8,562,500	'
Proceeds from employee stock option exercise	12,600	'
Proceeds from subscriptions payable for Senior Secured Notes	'	1,570,000
Proceeds from sale of capital stock - subscription agreement	'	75,000
Payments of principal on convertible promissory notes	-450,000	'
Payments of principal on promissory notes	-90,000	'
Payments of principal on capital lease	-1,292	-1,199
NET CASH PROVIDED BY FINANCING ACTIVITIES	9,173,808	1,643,801
EFFECT OF EXCHANGE RATES ON CASH	-1,432	-6,925
NET INCREASE IN CASH AND CASH EQUIVALENTS	7,049,631	600,702
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	182,315	70,325
CASH AND CASH EQUIVALENTS, END OF PERIOD	7,231,946	671,027
SUPPLEMENTAL INFORMATION	'	'
Cash paid for interest, related parties	164,765	81,864
8% Convertible Promissory Notes [Member]	'	'
Adjustments to reconcile net loss to net cash used by operating activities	'	'
Acretion of interest	339,864	'
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from promissory notes	325,000	'
Senior Secured Notes [Member]	'	'
Adjustments to reconcile net loss to net cash used by operating activities	'	'
Acretion of interest	'	428,467
18% Convertible Promissory Notes [Member]	'	'
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from promissory notes	$815,000	'

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	Mar. 31, 2014
18% Convertible Promissory Notes	18.00%
18% promissory notes	18.00%

Note_1_Nature_of_the_Business

Note 1 - Nature of the Business	3 Months Ended
	Mar. 31, 2014
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	1	Nature of the Business

	SANUWAVE Health, Inc. and subsidiaries (the “Company”) is a shockwave technology company using a patented system of noninvasive, high-energy, acoustic shockwaves for regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive, acoustic shockwaves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE^® device, which is in a supplemental Phase III clinical study for treating diabetic foot ulcers with possible FDA approval in 2015, subject to submission of satisfactory clinical study results.

	The Company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The Company intends to apply its Pulsed Acoustic Cellular Expression (PACE^®) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions. The Company is not currently marketing any commercial products in the United States. Revenue is from sales of the European Conformity Marking (“CE Mark”) devices and accessories in Europe, Canada, Asia and Asia/Pacific.

	In addition, there are license/partnership opportunities for the Company’s shockwave technology for non-medical uses, including energy, water, food and industrial markets.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2	Summary of Significant Accounting Policies

	Basis of Presentation

	The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by United States generally accepted accounting principles for complete financial statements. The financial information as of March 31, 2014 and for the three months ended March 31, 2014 and 2013 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2014.

	The condensed consolidated balance sheet at December 31, 2013 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by United States generally accepted accounting principles for complete financial statements.

	Financial condition

	Since inception in 2005, the Company’s operations have primarily been funded from the sale of capital stock and convertible debt securities. At March 31, 2014, the Company had cash and cash equivalents totaling $7,231,946. The Company does not currently generate significant recurring revenue and will require additional capital in the second half of 2015 to commercialize the dermaPACE, assuming positive clinical study results and FDA approval. Although no assurances can be given, management of the Company believes that existing capital resources should enable the Company to fund operations for at least the next twelve months. Accordingly, the accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

	Significant Accounting Policies

	For further information and a summary of significant accounting policies, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, filed with the SEC on March 31, 2014.

	Recently Issued Accounting Standards

	There have been no recently issued accounting standards that are expected to have a material impact on our condensed consolidated financial statements.

Note_3_Property_and_Equipment

Note 3 - Property and Equipment	3 Months Ended
Note 3 - Property and Equipment	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	3	Property and equipment

	Property and equipment consists of the following:

			March 31,			December 31,
			2014			2013

	Machines and equipment		$	235,738		$	233,793
	Office and computer equipment			171,404			171,404
	Software			41,872			41,872
	Furniture and fixtures			22,447			22,447
	Other assets			2,446			2,446
	Total			473,907			471,962
	Accumulated depreciation			(463,410	)		(458,695	)
	Net property and equipment		$	10,497		$	13,267

	The aggregate depreciation related to property and equipment charged to operations was $4,715 and $4,991 for the three months ended March 31, 2014 and 2013, respectively.

Note_4_Intangible_Assets

Note 4 - Intangible Assets	3 Months Ended
Note 4 - Intangible Assets	Mar. 31, 2014
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	4	Intangible assets

	Intangible assets consist of the following:

			March 31,			December 31,
			2014			2013

	Patents, at cost		$	3,502,135		$	3,502,135
	Less accumulated amortization			(2,658,555	)		(2,581,866	)
	Net intangible assets		$	843,580		$	920,269

	The aggregate amortization charged to operations was $76,689 for the three months ended March 31, 2014 and 2013.

Note_5_Accrued_expenses

Note 5 - Accrued expenses	3 Months Ended
Note 5 - Accrued expenses	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	5	Accrued expenses

	Accrued expenses consist of the following:

			March 31,		December 31,
			2014		2013

	Accrued executive severance		$	400,000	$	400,000
	Accrued consultants			79,100		58,000
	Accrued legal professional fees			50,000		29,500
	Accrued audit and tax preparation			25,760		91,000
	Accrued clinical study expenses			23,285		188,927
	Accrued board of directors fees			12,000		37,333
	Accrued other			45,018		58,812
			$	635,163	$	863,572

Note_6_18_Senior_secured_conve

Note 6 - 18% Senior secured convertible promissory notes

3 Months Ended

Mar. 31, 2014

Secured Convertible Promissory Notes [Abstract]

Secured Convertible Promissory Notes [Text Block]

18% Senior secured convertible promissory notes

During the period from November 2012 through March 8, 2013, the Company entered subscriptions payable for 18% senior secured convertible promissory notes (the “Senior Secured Notes”) from select accredited investors. The Company completed the offering and issued an aggregate $2,000,000 in Senior Secured Notes on March 8, 2013. As of March 31, 2013, the Company had outstanding $2,000,000 in Senior Secured Notes and had $66,520 in accrued interest expense. As of December 31, 2012, the Company had received subscriptions payable for Senior Secured Notes in the aggregate principal amount of $430,000 and had accrued interest expense of $8,516.

The Senior Secured Notes have a six month term from the subscription date and the note holders can convert into Company common stock at anytime during the term at a conversion price of $0.20 per share. Upon the consummation of a qualified financing and/or technology license, as defined in the Senior Secured Note agreements, as amended, of $4,000,000 or more by the Company, the principal and interest on the Senior Secured Notes will automatically convert into Company common stock equal to the lower of (i) the Company common stock issued in the qualified financing and/or technology license, reduced by a discount of 20%, and (ii) $0.20 per share. The note holders will also receive, if any are issued, warrants or any other securities issued in a qualified financing and/or technology license on similar terms to the qualified financing and/or technology license. The Senior Secured Notes are secured by the tangible and intangible assets of the Company.

The conversion feature embedded in the Senior Secured Notes was accounted for as a derivative liability and resulted in the creation at issuance of a discount to the carrying amount of the debt in the amount of $2,000,000, which was amortized as additional interest expense using the straight-line method over the term of the Senior Secured Notes (the Company determined that using the straight-line method of amortization did not yield a materially different amortization schedule than the effective interest method). The amount of the fair value of the embedded conversion feature in the Senior Secured Notes of $4,908,000, at the date of issuance, less the debt discount, totaled $2,908,000 and was recorded in the “loss on embedded conversion feature of Senior Secured Notes” in the accompanying consolidated statements of comprehensive loss; subsequent fair value adjustments of the embedded conversion feature of $829,000 at March 31, 2013 is also included in this financial statement caption.

The following table sets forth a summary of changes in the fair value of the derivative liability for the three months ended March 31, 2013:

Description

Balance at December 31, 2012

New Issuance

Change in Fair Value

Balance at March 31, 2013

Derivative liability:

Embedded conversion feature of Senior Secured Notes

4,908,000

829,000

5,737,000

On July 31, 2013, all of the holders of the Senior Secured Notes voluntarily converted all of the outstanding principal and interest of the Senior Secured Notes into Company common stock. The aggregate outstanding amount of principal and interest on the Senior Secured Notes at July 31, 2013 of $2,186,906 was converted into 10,934,533 shares of Company common stock at the conversion price of $0.20 per share - the market price at the time the subscription agreement was written - pursuant to the Senior Secured Note agreements. In return for the holders’ voluntarily converting the outstanding Senior Secured Notes on or before July 31, 2013, the Company agreed to issue to the holders warrants to purchase an aggregate total of 1,988,095 shares of Company common stock (the “Class H Warrants”). The Class H Warrants have an exercise price of $0.80 per share and are exercisable during the five-year period beginning on the date of issuance. In July 2013, the Company recorded a loss from extinguishment of debt of $1,073,572, which was the estimated fair value of the warrants issued to the holders on the date of exchange calculated using the Black-Scholes pricing model using the following primary inputs of: (i) $0.60 closing stock price on the date of grant, (ii) the expected time the warrants will be outstanding of five-years, (iii) estimated discount rate of 1.38%, and (iv) expected volatility of 149% based on historical data from companies similar in size and value to the Company.

Kevin A. Richardson, II, chairman of the board of directors of the Company, converted an aggregate balance of $64,500 of the Senior Secured Notes and received 322,500 shares of Company common stock and 58,635 Class H Warrants in the foregoing transaction.

Accrued interest expense on the Senior Secured Notes, including amortization of the debt discount, totaled $428,467 for the three months ended March 31, 2013.

Note_7_Notes_Payable_Related_P

Note 7 - Notes Payable, Related Parties	3 Months Ended
Note 7 - Notes Payable, Related Parties	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	7	Notes payable, related parties

	The notes payable, related parties consist of the following:

			March 31,		December 31,
			2014		2013
	Notes payable, unsecured, payable to
	HealthTronics, Inc., a shareholder of the Company		$	5,372,743	$	5,372,743
	Less current portion			-		-
	Non-current portion		$	5,372,743	$	5,372,743

	The notes payable, related parties were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. on August 1, 2005. The notes payable, related parties bear interest at 6% per annum. Quarterly interest through June 30, 2010, was accrued and added to the principal balance. Interest is paid quarterly in arrears beginning September 30, 2010. All remaining unpaid accrued interest and principal is due August 1, 2015. Accrued interest currently payable totaled $80,072 and $163,729 at March 31, 2014 and December 31, 2013, respectively.

	Interest expense on notes payable to related parties totaled $81,108 and $80,071 for the three months ended March 31, 2014 and 2013, respectively.

Note_8_Income_Taxes

Note 8 - Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	8	Income taxes

	The Company files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to United States federal and state and non-United States income tax examinations by tax authorities for years before 2010.

	At March 31, 2014, the Company had federal net operating loss (“NOL”) carryforwards of $59,299,144 for tax years through the year ended December 31, 2013, that will begin to expire in 2025. The use of deferred tax assets, including federal net operating losses, is limited to future taxable earnings. Based on the required analysis of future taxable income under the provisions of ASC 740, Income Taxes (formerly SFAS No. 109), the Company’s management believes that there is not sufficient evidence at March 31, 2014 indicating that the results of operations will generate sufficient taxable income to realize the net deferred tax asset in years beyond 2014. As a result, a valuation allowance was provided for the entire net deferred tax asset related to future years, including NOL carryforwards.

	The Company’s ability to use its NOL carryforwards could be limited and subject to annual limitations. In connection with future offerings, the Company may realize a “more than 50% change in ownership” which could further limit its ability to use its NOL carryforwards accumulated to date to reduce future taxable income and tax liabilities. Additionally, because United States tax laws limit the time during which NOL carryforwards may be applied against future taxable income and tax liabilities, the Company may not be able to take advantage of all or portions of its NOL carryforwards for federal income tax purposes.

Note_9_Equity_Transactions

Note 9 - Equity Transactions	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	9	Equity transactions

	2014 Private Placement

	On March 17, 2014, in conjunction with a private placement of securities (the “2014 Private Placement”) with institutional and select accredited investors, the Company issued an aggregate total of 6,210,000 shares of common stock and 6,175 shares of preferred stock (the “Series A Convertible Preferred Stock”) for an aggregate total purchase price of $9,280,000. Each share of Series A Convertible Preferred Stock is convertible into 2,000 shares of common stock at the option of the holder. The net proceeds received by the Company were $8,562,500, net of offering costs of $717,500.

	The Company, in connection with the 2014 Private Placement, issued to the investors an aggregate total of 23,200,000 warrants (the “Series A Warrants”) to purchase shares of common stock at an exercise price of $0.50 per share. Each Series A Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire after five years.

	In addition, the Company, in connection with the 2014 Private Placement, issued to the investors an aggregate total of 13,920,000 warrants (the “Series B Warrants”) to purchase shares of common stock at an exercise price of $1.50 per share. Each Series B Warrant represents the right to purchase one share of Common Stock. The warrants vested upon issuance and expire after one year.

	Pursuant to the terms of a registration rights agreement that the Company entered with the investors in connection with the 2014 Private Placement, the Company filed a registration statement with the SEC in April 2014 that covers the shares of common stock and the shares of common stock issuable upon conversion of the Series A Convertible Preferred Stock and exercise of the Series A Warrants and Series B Warrants. The registration statement was declared effective by the SEC on May 6, 2014.

	Kevin A. Richardson, II, chairman of the board of directors of the Company and Co-Chief Executive Officer; Joseph Chiarelli, the former Chief Executive Officer of the Company and a member of the Company’s board of directors; and, Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, were purchasers in the 2014 Private Placement of $50,000, $40,000 and $50,000, respectively.

	At the closing of the 2014 Private Placement, the Company paid Newport Coast Securities, Inc., the placement agent for the private placement, and Oppenheimer & Co. Inc., the former placement agent, cash compensation based on the gross proceeds of the private placement and 696,000 Series A Warrants and 417,600 Series B Warrants.

	18% Convertible Promissory Notes

	During the period January 24, 2014 through March 7, 2014, the Company entered into subscriptions payable for 18% convertible promissory notes, as amended, (the “18% Convertible Promissory Notes”) from selected accredited investors. Up to $1,000,000 aggregate principal amount of 18% Convertible Promissory Notes were offered by the Company. The Company completed the offering and issued an aggregate $815,000 in convertible notes in March 2014. Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, purchased $110,000 of the convertible notes.

	The 18% Convertible Promissory Notes have a nine month term from the subscription date and the note holders can convert into Company common stock at anytime during the term at $0.55 per share. Upon the consummation of a qualified financing, as defined in the convertible note agreements, of $1,000,000 or more by the Company, the principal and interest on the 18% Convertible Promissory Notes convert into Company common stock equal to the lower of (i) the Company common stock issued in the qualified financing, and (ii) $0.55 per share. The note holders also receive, if any are issued, warrants or any other security issued in a qualified financing on similar terms to the qualified financing. The 18% Convertible Promissory Notes are unsecured.

	The 2014 Private Placement was a qualified financing as defined in the 18% Convertible Promissory Notes. As such, on March 17, 2014, in conjunction with the 2014 Private Placement discussed above, the 18% Convertible Promissory Notes, with an aggregate outstanding principal and accrued interest balance of $822,168, were automatically converted and the holders received in the aggregate 1,644,337 shares of common stock. In addition, the holders received an aggregate total of 2,055,421 Series A Warrants and 1,233,252 Series B Warrants.

	$278,500 Convertible Promissory Note and Warrants

	On February 10, 2014, the Company entered into a financing transaction with an accredited investor for the sale of an 8% convertible promissory note (the “$278,500 Convertible Note”) and warrants (the “Class J Warrants”) in the principal amount of $278,500, with gross proceeds of $250,000 to the Company after payment of a 10% original issue discount and related professional expenses.

	The $278,500 Convertible Note and Class J Warrants were issued pursuant to the terms of a purchase agreement among the Company and the holder. The convertible note is an unsecured obligation of the Company and, unless earlier redeemed, matures on August 11, 2014. The convertible note bears interest accruing at the rate of 8% per annum and includes a 10%, or $25,000, original issuance discount. The Company has the right to prepay the convertible note and accrued interest during the first 180 days following the date of issuance. During that time, the amount of any prepayment during the first 60 days is 120% of the outstanding amounts owed, and the amount of the prepayment increases every subsequent 30 days. The $278,500 Convertible Note is convertible, after the first 180 days, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of the lower of 75% of the lowest reported sale price of the Company’s common stock for the 20 trading days immediately prior to (i) the closing date of the financing, or (ii) 75% of the lowest reported sale price for the 20 days prior the conversion date of the convertible note. The convertible note includes full ratchet anti-dilution protection for any lower priced issuances of common stock or securities convertible or exchangeable into Company common stock.

	The Class J Warrants entitle the holder to purchase, in the aggregate, 629,378 shares of the Company’s common stock. The Warrants will not be exercisable until the six month anniversary of the closing date (August 10, 2014) and will expire five years from the closing date. The Class J Warrants have an exercise price equal to $0.4425. The Class J Warrants may be exercised for cash or on a cashless basis. The exercise price of the warrants is subject to adjustment for stock splits, combinations or similar events, and, in this event, the number of shares issuable upon the exercise of the warrant will also be adjusted so that the aggregate exercise price shall be the same immediately before and immediately after the adjustment. In addition, the exercise price is also subject to a “full ratchet” anti-dilution adjustment where if the Company issues or is deemed to have issued securities at a price lower than the then applicable exercise price.

	In the first quarter of 2014, the Company recorded additional interest expense of $339,864, which was the estimated fair value of the Class J Warrants on the date of grant, February 10, 2014, calculated using the Black-Scholes pricing model using the following primary inputs of: (i) $0.60 closing stock price on the date of grant, (ii) the expected time the warrants will be outstanding of five-years, (iii) estimated discount rate of 1.48%, and (iv) expected volatility of 137% based on historical data from the Company and other companies similar in size and value to the Company.

	In March 2014, the Company repaid the $278,500 Convertible Note in full which totaled $337,171 with accrued interest and a prepayment penalty of $56,195.

	$128,500 Convertible Promissory Note

	On December 23, 2013, the Company entered into a financing transaction with an accredited investor for the sale of an 8% convertible promissory note (the “$128,500 Convertible Note”) in the principal amount of $128,500, with gross proceeds of $125,000 to the Company after payment of related professional expenses.

	The $128,500 Convertible Note was issued pursuant to the terms of a purchase agreement among the Company and the accredited investor. The convertible note is an unsecured obligation of the Company and, unless earlier redeemed, matures on September 26, 2014. The convertible note bears interest accruing at the rate of 8% per annum. The Company has the right to prepay the convertible note and accrued interest during the first 180 days following the date of issuance. During that time, the amount of any prepayment during the first 30 days is 115% of the outstanding amounts owed, and the amount of the prepayment increases every subsequent 30 days.

	The $128,500 Convertible Note is convertible, after the first 180 days, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of 61% of the lowest three reported sale prices of the Company’s common stock for the 10 trading days immediately prior to the conversion date. The convertible note includes full ratchet anti-dilution protection for any lower priced issuances of common stock or securities convertible or exchangeable into Company common stock.

	In March 2014, the Company repaid the $128,500 Convertible Note in full which totaled $158,055, with accrued interest and prepayment penalty of $29,555.

	$78,500 Convertible Promissory Note

	On February 18, 2014, the Company entered into a second tranche of financing with the accredited investor for the $128,500 Convertible Note for the sale of 8% Convertible Promissory Note (the “$78,500 Convertible Note”) under the same terms as the first tranche in the principal amount of $78,500, with gross proceeds of $75,000 to the Company after payment of related professional expenses.

	The $78,500 Convertible Note was issued pursuant to the terms of a purchase agreement among the Company and the accredited investor. The convertible note is an unsecured obligation of the Company and, unless earlier redeemed, matures on November 20, 2014. The convertible note bears interest accruing at the rate of 8% per annum. The Company has the right to prepay the convertible note and accrued interest during the first 180 days following the date of issuance. During that time, the amount of any prepayment during the first 30 days is 115% of the outstanding amounts owed, and the amount of the prepayment increases every subsequent 30 days.

	The $78,500 Convertible Note is convertible, after the first 180 days, in whole or in part, at the option of the investor, into shares of Company common stock at a conversion price of 61% of the lowest three reported sale prices of the Company’s common stock for the 10 trading days immediately prior to the conversion date. The convertible note includes full ratchet anti-dilution protection for any lower priced issuances of common stock or securities convertible or exchangeable into Company common stock.

	In March 2014, the Company repaid the $78,500 Convertible Note in full which totaled $90,275 with accrued interest and prepayment penalty of $11,775.

	Consulting Agreements

	In February 2014, the Company renewed one consulting contract and entered into three additional consulting agreements for which a portion of the fee for the services performed was paid with Company common stock. The Company issued 835,000 shares of common stock under these new agreements in February and March, 2014. The fair value of the common stock issued to the consultants, based upon the closing market price of the Company’s common stock at the dates the common stock was issued, was recorded as a non-cash general and administrative expense for the three months ended March 31, 2014.

Note_10_Preferred_Stock

Note 10 - Preferred Stock	3 Months Ended
	Mar. 31, 2014
Disclosure Text Block Supplement [Abstract]	'
Preferred Stock [Text Block]	'
	10	Preferred Stock

	The Company’s articles of incorporation authorize the issuance of up to 5,000,000 shares of “blank check” preferred stock with designations, rights and preferences as may be determined from time to time by the board of directors. On March 14, 2014, the Company filed a Certificate of Designation of Preferences, Rights and Limitations for Series A Convertible Preferred Stock of the Company (the “Certificate of Designation”) with the Nevada Secretary of State. The Certificate of Designation amends the Company’s Articles of Incorporation to designate 6,175 shares of preferred stock, par value $0.001 per share, as Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock has a stated value of $1,000 per share. On March 17, 2014, in connection with the 2014 Private Placement, the Company issued 6,175 shares of Series A Convertible Preferred Stock (for a more detailed discussion regarding the 2014 Private Placement, see Note 9).

	Under the Certificate of Designation, holders of Series A Convertible Preferred Stock are entitled to receive dividends equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, as and if such dividends are paid. Such holders will participate on an equal basis per-share with holders of common stock in any distribution upon winding up, dissolution, or liquidation of the Company. Holders of Series A Convertible Preferred Stock are entitled to convert each share of Series A Preferred Stock into 2,000 shares of common stock, provided that after giving effect to such conversion, such holder, together with its affiliates, shall not beneficially own in excess of 9.99% of the number of shares of common stock outstanding (the “Beneficial Ownership Limitation”). Holders of the Series A Convertible Preferred Stock are entitled to vote on all matters affecting the holders of the common stock on an “as converted” basis, provided that such holder shall only vote such shares of Series A Convertible Preferred Stock eligible for conversion without exceeding the Beneficial Ownership Limitation.

Note_11_Warrants

Note 11 - Warrants	3 Months Ended
Note 11 - Warrants	Mar. 31, 2014
Warrants [Abstract]	'
Warrants [Text Block]	'
	11	Warrants

	A summary of the warrant activity as of March 31, 2014 and December 31, 2013, and the changes during the three months ended March 31, 2014, is presented as follows:

			Outstanding								Outstanding
			as of								as of
			December 31,								March 31,		Exercise		Expiration
	Warrant class		2013		Issued		Exercised		Expired		2014		price/share		date

	Class A Warrants			1,106,627		-		-		-		1,106,627	$	4	Sept, 2014
	Class B Warrants			1,106,627		-		-		-		1,106,627	$	8	Sept, 2014
	Class E Warrants			3,576,737		-		-		-		3,576,737	$	4	Apr, 2016
	Class F Warrants			300,000		-		-		-		300,000	$	0.35	Feb, 2018
	Class G Warrants			1,503,409		-		-		-		1,503,409	$	0.8	Jul, 2018
	Class H Warrants			1,988,095		-		-		-		1,988,095	$	0.8	Jul, 2018
	Class I Warrants			1,043,646		-		-		-		1,043,646	$	0.85	Sept, 2018
	Class J Warrants			-		629,378		-		-		629,378	$	0.44	Feb, 2019
	Series A Warrants			-		25,951,421		-		-		25,951,421	$	0.5	Mar, 2019
	Series B Warrants			-		15,570,852		-		-		15,570,852	$	1.5	Mar, 2015
				10,625,141		42,151,651		-		-		52,776,792

Note_12_Commitments_and_Contin

Note 12 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	12	Commitments and contingencies

	Subscription agreement

	On November 27, 2012, the Company and David N. Nemelka (the “Subscriber”), the brother of John F. Nemelka, a member of the Company’s board of directors, entered into a subscription agreement (the “Subscription Agreement”) whereby the Subscriber has agreed to purchase from the Company, and the Company has agreed to sell and issue, a total of 4,000,000 shares of the Company’s unregistered common stock at a purchase price equal to $0.25 per share, for an aggregate sales price of $1,000,000 (the “Purchase Price”). The shares are subject to piggy-back registration rights if the Company files a registration statement for an offering of securities.

	The Purchase Price shall be payable to the Company as follows: (i) $50,000 on or before January 31, 2013; (ii) $50,000 on or before February 15, 2013; and (iii) the balance of $900,000 on or before May 27, 2014 (the “Outside Due Date”). The Subscriber may make payments of the Purchase Price at his discretion in minimum installments of $100,000 each, until the Outside Due Date.

	In the event that at any time after February 15, 2013, the Company’s total available cash should be less than $100,000, the Subscriber shall, upon demand of the Company, pay to the Company $100,000 of the then outstanding balance of the Purchase Price, which payment shall be due within thirty (30) days of the demand. There is no limit on the number of demands that the Company may make pursuant to this provision of the Subscription Agreement, provided, however, that in no event shall the Company provide more than one notice of demand for payment in any 30 day period.

	As of March 31, 2014, the Subscriber had paid the Company $100,000 and was issued 400,000 shares of unregistered common stock of the Company. The Company will record the additional $900,000 and issue the corresponding 3,600,000 shares of common stock in the periods in which the Purchase Price is received.

	Operating Leases

	Rent expense for the three months ended March 31, 2014 and 2013, was $29,934 and $27,474, respectively.

	Litigation

	The Company is involved in various legal matters that have arisen in the ordinary course of business. While the ultimate outcome of these matters is not presently determinable, it is the opinion of management that the resolution will not have a material adverse effect on the financial position or results of operations of the Company.

Note_13_Stockbased_Compensatio

Note 13 - Stock-based Compensation	3 Months Ended
Note 13 - Stock-based Compensation	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	13	Stock-based compensation

	On November 1, 2010, the Company approved the Amended and Restated 2006 Stock Incentive Plan of SANUWAVE Health, Inc. effective as of January 1, 2010 (the “Stock Incentive Plan”). The Stock Incentive Plan permits grants of awards to selected employees, directors and advisors of the Company in the form of restricted stock or options to purchase shares of common stock. Options granted may include non-statutory options as well as qualified incentive stock options. The Stock Incentive Plan is currently administered by the board of directors of the Company. The Stock Incentive Plan gives broad powers to the board of directors of the Company to administer and interpret the particular form and conditions of each option. The stock options granted under the Stock Incentive Plan are non-statutory options which generally vest over a period of up to four years and have a ten year term. The options are granted at an exercise price determined by the board of directors of the Company to be the fair market value of the common stock on the date of the grant. At March 31, 2014 and December 31, 2013, the Stock Incentive Plan reserved 8,500,000 shares of common stock for grant.

	There were no stock options grants during the three months ended March 31, 2014. For the three months ended March 31, 2013, the Company made the following stock option grants:

	On February 21, 2013, the Company, by mutual agreement with all the active employees and directors of the Company, cancelled options granted to the active employees in the year ended December 31, 2011 and prior which totaled 1,113,644 shares of common stock at an average exercise price of $2.92. In exchange for these options, the active employees and directors received new options to purchase 2,243,644 shares of common stock at an exercise price of $0.35 per share. Using the Black-Scholes option pricing model, management has determined that the options at the grant date, net of the value of the cancelled options as of the date of cancellation, had an average fair value per share of $0.223 resulting in total compensation of $499,621. Compensation cost will be recognized over the requisite service period.

	On February 21, 2013, the Company granted two members of the Company’s Medical Advisory Board each options to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.35 per share in place of an annual cash consulting fee for calendar year 2013. Using the Black-Scholes option pricing model, management has determined that the options had a fair value per share of $0.64 resulting in compensation expense of $64,000. Compensation cost will be recognized over the calendar year 2013.

	On February 25, 2013, Joseph Chiarelli joined the Company to serve as the Chief Executive Officer and a director of the Company. Mr. Chiarelli was granted options to purchase 2,250,000 shares of the Company’s common stock at an exercise price of $0.35 per share. The options vest and become exercisable in five installments as follows: (i) 375,000 vested at grant; (ii) 375,000 vest upon the Company completing a financing resulting in gross proceeds to the Company of no less than $5,000,000 at a price per share of not less than $0.35; (iii) 375,000 upon the execution by the Company of a license or distribution agreement from which the Company is entitled to receive gross proceeds of no less than $1,000,000 and the Company has received payments of at least $250,000; (iv) 375,000 vest upon receipt by the Company of FDA approval for the use of dermaPACE; and (v) 750,000 vest in the event the Company achieves the milestones (i), (ii), (iii) and (iv) above during the initial two year term and the term is not extended by the Company. Using the Black-Scholes option pricing model, management has determined that the options had an average fair value per share of $0.207 resulting in total compensation of $465,000. Compensation cost will be recognized over the requisite service period.

	The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions for the three months ended March 31, 2013:

			2013
	Weighted average expected life in years			4.3
	Weighted average risk free interest rate			0.72	%
	Weighted average volatility			150	%
	Forfeiture rate			0	%
	Expected dividend yield			0	%

	The expected life of options granted represent the period of time that options granted are expected to be outstanding and are derived from the contractual terms of the options granted. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. Since there is a limited trading history for the Company’s common stock, the expected volatility is based on a combination of historical data from companies similar in size, value and trading history for the Company’s common stock. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. Management estimates pre-vesting forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. Ultimately, the total expense recognized over the vesting period will equal the fair value of the awards that actually vest. The expected dividend yield is based on historical dividend experience, however, since inception the Company has not declared dividends.

	The Company recognized as compensation cost for all outstanding stock options granted to employees, directors and advisors, $70,778 and $317,601 for the three months ended March 31, 2014 and 2013, respectively.

	A summary of option activity as of March 31, 2014 and December 31, 2013, and the changes during the three months ended March 31, 2014, is presented as follows:

						Weighted
						Average
						Exercise Price
			Options			per share
	Outstanding as of December 31, 2013			8,366,830		$	1.17
	Granted			-		$	-
	Exercised			(60,000	)	$	0.21
	Cancelled			-		$	-
	Forfeited or expired			-		$	-
	Outstanding as of March 31, 2014			8,306,830		$	1.17

	Exercisable			6,067,290		$	1.48

	The range of exercise prices for options was $0.21 to $2.92 for options outstanding at March 31, 2014 and December 31, 2013. The aggregate intrinsic value for the exercised options was $28,900 for the three months ended March 31, 2014. The aggregate intrinsic value for outstanding options was $1,895,078 and $1,271,540 at March 31, 2014 and December 31, 2013, respectively. The aggregate intrinsic value for all vested and exercisable options was $1,142,029 and $574,181 at March 31, 2014 and December 31, 2013, respectively.

	The weighted average remaining contractual term for outstanding exercisable stock options is 7.06 years as of March 31, 2014 and 6.96 years as of December 31, 2013.

	A summary of the Company’s nonvested options as of March 31, 2014 and December 31, 2013, and changes during the three months ended March 31, 2014, is presented as follows:

						Weighted
						Average
						Exercise Price
			Options			per share
	Outstanding as of December 31, 2013			3,254,092		$	0.35
	Granted			-		$	-
	Vested			(1,014,552	)	$	0.35
	Cancelled			-		$	-
	Forfeited or expired			-		$	-
	Outstanding as of March 31, 2014			2,239,540		$	0.34

Note_14_Earnings_Loss_Per_Shar

Note 14 - Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	14	Earnings (loss) per share

	The Company calculates net income (loss) per share in accordance with ASC 260, Earnings Per Share (formerly SFAS No. 128, Earnings Per Share). Under the provisions of ASC 260, basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of shares of common stock outstanding for the period. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents then outstanding. To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share.

	As a result of the net loss for the three months ended March 31, 2014 and 2013, respectively, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share. The anti-dilutive equity securities totaled 73,433,622 shares and 26,726,924 shares at March 31, 2014 and 2013, respectively.

Note_3_Property_and_Equipment_

Note 3 - Property and Equipment (Tables)	3 Months Ended
Note 3 - Property and Equipment (Tables)	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		March 31,			December 31,
		2014			2013

	Machines and equipment	$	235,738		$	233,793
	Office and computer equipment		171,404			171,404
	Software		41,872			41,872
	Furniture and fixtures		22,447			22,447
	Other assets		2,446			2,446
	Total		473,907			471,962
	Accumulated depreciation		(463,410	)		(458,695	)
	Net property and equipment	$	10,497		$	13,267

Note_4_Intangible_Assets_Table

Note 4 - Intangible Assets (Tables)	3 Months Ended
Note 4 - Intangible Assets (Tables)	Mar. 31, 2014
Disclosure Text Block [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
		March 31,			December 31,
		2014			2013

	Patents, at cost	$	3,502,135		$	3,502,135
	Less accumulated amortization		(2,658,555	)		(2,581,866	)
	Net intangible assets	$	843,580		$	920,269

Note_5_Accrued_expenses_Tables

Note 5 - Accrued expenses (Tables)	3 Months Ended
Note 5 - Accrued expenses (Tables)	Mar. 31, 2014
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
		March 31,		December 31,
		2014		2013

	Accrued executive severance	$	400,000	$	400,000
	Accrued consultants		79,100		58,000
	Accrued legal professional fees		50,000		29,500
	Accrued audit and tax preparation		25,760		91,000
	Accrued clinical study expenses		23,285		188,927
	Accrued board of directors fees		12,000		37,333
	Accrued other		45,018		58,812
		$	635,163	$	863,572

Note_6_18_Senior_secured_conve1

Note 6 - 18% Senior secured convertible promissory notes (Tables)

3 Months Ended

Mar. 31, 2014

Secured Convertible Promissory Notes [Abstract]

Schedule of Derivative Liabilities at Fair Value [Table Text Block]

Description

Balance at December 31, 2012

New Issuance

Change in Fair Value

Balance at March 31, 2013

Derivative liability:

Embedded conversion feature of Senior Secured Notes

4,908,000

829,000

5,737,000

Note_7_Notes_Payable_Related_P1

Note 7 - Notes Payable, Related Parties (Tables)	3 Months Ended
Note 7 - Notes Payable, Related Parties (Tables)	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		March 31,		December 31,
		2014		2013
	Notes payable, unsecured, payable to
	HealthTronics, Inc., a shareholder of the Company	$	5,372,743	$	5,372,743
	Less current portion		-		-
	Non-current portion	$	5,372,743	$	5,372,743

Note_11_Warrants_Tables

Note 11 - Warrants (Tables)	3 Months Ended
Note 11 - Warrants (Tables)	Mar. 31, 2014
Warrants [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		Outstanding								Outstanding
		as of								as of
		December 31,								March 31,		Exercise		Expiration
	Warrant class	2013		Issued		Exercised		Expired		2014		price/share		date

	Class A Warrants		1,106,627		-		-		-		1,106,627	$	4	Sept, 2014
	Class B Warrants		1,106,627		-		-		-		1,106,627	$	8	Sept, 2014
	Class E Warrants		3,576,737		-		-		-		3,576,737	$	4	Apr, 2016
	Class F Warrants		300,000		-		-		-		300,000	$	0.35	Feb, 2018
	Class G Warrants		1,503,409		-		-		-		1,503,409	$	0.8	Jul, 2018
	Class H Warrants		1,988,095		-		-		-		1,988,095	$	0.8	Jul, 2018
	Class I Warrants		1,043,646		-		-		-		1,043,646	$	0.85	Sept, 2018
	Class J Warrants		-		629,378		-		-		629,378	$	0.44	Feb, 2019
	Series A Warrants		-		25,951,421		-		-		25,951,421	$	0.5	Mar, 2019
	Series B Warrants		-		15,570,852		-		-		15,570,852	$	1.5	Mar, 2015
			10,625,141		42,151,651		-		-		52,776,792

Note_13_Stockbased_Compensatio1

Note 13 - Stock-based Compensation (Tables)	3 Months Ended
Note 13 - Stock-based Compensation (Tables)	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		2013
	Weighted average expected life in years		4.3
	Weighted average risk free interest rate		0.72	%
	Weighted average volatility		150	%
	Forfeiture rate		0	%
	Expected dividend yield		0	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
					Weighted
					Average
					Exercise Price
		Options			per share
	Outstanding as of December 31, 2013		8,366,830		$	1.17
	Granted		-		$	-
	Exercised		(60,000	)	$	0.21
	Cancelled		-		$	-
	Forfeited or expired		-		$	-
	Outstanding as of March 31, 2014		8,306,830		$	1.17

	Exercisable		6,067,290		$	1.48
Schedule of Other Share-based Compensation, Activity [Table Text Block]	'
					Weighted
					Average
					Exercise Price
		Options			per share
	Outstanding as of December 31, 2013		3,254,092		$	0.35
	Granted		-		$	-
	Vested		(1,014,552	)	$	0.35
	Cancelled		-		$	-
	Forfeited or expired		-		$	-
	Outstanding as of March 31, 2014		2,239,540		$	0.34

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	$7,231,946	$182,315	$671,027	$70,325

Note_3_Property_and_Equipment_1

Note 3 - Property and Equipment (Details) (USD $)	3 Months Ended		15 Months Ended
Note 3 - Property and Equipment (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'	'	'
Depreciation	$4,715	$4,991	$4,991

Note_3_Property_and_Equipment_2

Note 3 - Property and Equipment (Details) - Property and Equipment (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	$473,907	$471,962
Accumulated depreciation	-463,410	-458,695
Net property and equipment	10,497	13,267
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	235,738	233,793
Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	171,404	171,404
Software Development [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	41,872	41,872
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	22,447	22,447
Property, Plant and Equipment, Other Types [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	$2,446	$2,446

Note_4_Intangible_Assets_Detai

Note 4 - Intangible Assets (Details) (USD $)	3 Months Ended
Note 4 - Intangible Assets (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Disclosure Text Block [Abstract]	'	'
Amortization of Intangible Assets	$76,689	$76,689

Note_4_Intangible_Assets_Detai1

Note 4 - Intangible Assets (Details) - Intangible Assets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Intangible Assets [Abstract]	'	'
Patents, at cost	$3,502,135	$3,502,135
Less accumulated amortization	-2,658,555	-2,581,866
Net intangible assets	$843,580	$920,269

Note_5_Accrued_expenses_Detail

Note 5 - Accrued expenses (Details) - Accrued Expenses (USD $)	Mar. 31, 2014	Dec. 31, 2013
Note 5 - Accrued expenses (Details) - Accrued Expenses [Line Items]	'	'
Accrued executive severance	$400,000	$400,000
Accrued consultants	79,100	58,000
Accrued clinical study expenses	23,285	188,927
Accrued board of directors fees	12,000	37,333
Accrued other	45,018	58,812
	635,163	863,572
Legal and Professional Fees [Member]	'	'
Note 5 - Accrued expenses (Details) - Accrued Expenses [Line Items]	'	'
Accrued professional fees	50,000	29,500
Audit and Tax Preparation [Member]	'	'
Note 5 - Accrued expenses (Details) - Accrued Expenses [Line Items]	'	'
Accrued professional fees	$25,760	$91,000

Note_6_18_Senior_secured_conve2

Note 6 - 18% Senior secured convertible promissory notes (Details) (USD $)

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

Jul. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Jul. 31, 2013

Mar. 31, 2014

Mar. 08, 2013

Jul. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2012

Class H Warrants [Member]

Board of Directors Chairman [Member]

Senior Secured Notes [Member]

Note 6 - 18% Senior secured convertible promissory notes (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18.00%

Notes Issued

$2,000,000

Convertible Notes Payable, Current

147,775

2,000,000

Interest Payable, Current

66,520

8,516

Debt Instrument, Face Amount

430,000

Debt Instrument, Term

'6 months

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$0.20

Debt Conversion, Original Debt, Amount

64,500

4,000,000

Debt Instrument, Convertible, Terms of Conversion Feature, Common Stock Discount

20.00%

Debt Instrument, Unamortized Discount

2,000,000

Embedded Derivative, Fair Value of Embedded Derivative Liability

5,737,000

4,908,000

Embedded Derivative, Loss on Embedded Derivative

3,737,000

2,908,000

Embedded Derivative, Fair Value Adjustment Of Embedded Derivative Liability

829,000

Secured Debt

2,186,906

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

322,500

10,934,533

Warrants Issued (in Shares)

42,151,651

1,988,095

58,635

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

0.8

Warrants Term

'5 years

Gains (Losses) on Extinguishment of Debt

-1,073,572

Share Price (in Dollars per share)

$0.60

Fair Value Assumptions, Expected Term

'5 years

Fair Value Inputs, Discount Rate

1.38%

Fair Value Assumptions, Expected Volatility Rate

149.00%

Debt Instrument, Increase, Accrued Interest

$7,168

$428,467

Note_6_18_Senior_secured_conve3

Note 6 - 18% Senior secured convertible promissory notes (Details) - Summary of Changes in the Fair Value of the Derivative Liability (USD $)	3 Months Ended
	Mar. 31, 2013
Summary of Changes in the Fair Value of the Derivative Liability [Abstract]	'
Embedded conversion feature of Senior Secured Notes	$4,908,000
Embedded conversion feature of Senior Secured Notes	829,000
Embedded conversion feature of Senior Secured Notes	$5,737,000

Note_7_Notes_Payable_Related_P2

Note 7 - Notes Payable, Related Parties (Details) (Note Payable To HealthTronics [Member], USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Note Payable To HealthTronics [Member]	'	'	'
Note 7 - Notes Payable, Related Parties (Details) [Line Items]	'	'	'
Related Party Transaction, Rate	'	'	6.00%
Interest Payable, Current	$80,072	'	$163,729
Interest Expense, Related Party	$81,108	$80,071	'

Note_7_Notes_Payable_Related_P3

Note 7 - Notes Payable, Related Parties (Details) - Notes Payable (USD $)	Mar. 31, 2014	Dec. 31, 2013
Notes payable, unsecured, payable to	'	'
HealthTronics, Inc., a shareholder of the Company	$5,372,743	$5,372,743
Non-current portion	$5,372,743	$5,372,743

Note_8_Income_Taxes_Details

Note 8 - Income Taxes (Details) (USD $)	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Operating Loss Carryforwards	$59,299,144

Note_9_Equity_Transactions_Det

Note 9 - Equity Transactions (Details) (USD $)

1 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

2 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Jul. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 17, 2014

Feb. 10, 2014

Dec. 23, 2013

Feb. 18, 2014

Mar. 31, 2014

Mar. 17, 2014

Mar. 31, 2014

Mar. 17, 2014

Mar. 31, 2014

Feb. 10, 2014

Mar. 31, 2014

Mar. 07, 2014

Mar. 17, 2014

Mar. 31, 2014

Mar. 17, 2014

Mar. 07, 2014

Feb. 10, 2014

Mar. 31, 2014

Dec. 23, 2013

Feb. 18, 2014

Mar. 31, 2014

Feb. 18, 2014

Private Placements [Member]

During First 60 Days [Member]

Consulting Agreements [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Class J Warrants [Member]

Michael N. Nemelka [Member]

Series A Preferred Stock [Member]

18% Convertible Promissory Notes [Member]

8% Convertible Promissory Notes [Member]

$128,500 Convertible Note [Member]

$78,500 Convertible Note [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Board of Directors Chairman [Member]

Joseph Chiarelli [Member]

Michael N. Nemelka [Member]

Series A Preferred Stock [Member]

8% Convertible Promissory Notes [Member]

$128,500 Convertible Note [Member]

$78,500 Convertible Note [Member]

18% Convertible Promissory Notes [Member]

Interest Expense [Member]

8% Convertible Promissory Notes [Member]

18% Convertible Promissory Notes [Member]

Common Stock [Member]

Newport Coast Securities, Inc and Oppenheimer & Co. Inc [Member]

Common Stock [Member]

Newport Coast Securities, Inc and Oppenheimer & Co. Inc [Member]

Note 9 - Equity Transactions (Details) [Line Items]

Stock Issued During Period, Shares, New Issues (in Shares)

6,175

6,210,000

6,175

Proceeds from Issuance of Private Placement, Gross

$50,000

$40,000

$50,000

$9,280,000

Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)

2,000

Proceeds from Issuance of Private Placement

8,562,500

Payments of Stock Issuance Costs

717,500

Warrants Issued (in Shares)

42,151,651

23,200,000

13,920,000

25,951,421

15,570,852

629,378

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

0.5

1.5

0.5

1.5

0.4425

0.44

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares)

Class of Warrants or Right, Exercisable Term

'5 years

'1 year

Class of Warrant or Right, Outstanding (in Shares)

52,776,792

10,625,141

696,000

417,600

2,055,421

25,951,421

1,233,252

15,570,852

629,378

Debt Instrument, Interest Rate, Stated Percentage

18.00%

8.00%

Debt Instrument, Face Amount

1,000,000

278,500

128,500

78,500

Proceeds from Convertible Debt

815,000

250,000

125,000

75,000

Due to Related Parties

110,000

Debt Instrument, Term

'9 months

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$0.55

Convertible Debt

822,168

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

1,644,337

Debt Instrument, Original Issuance Discount, Percent

10.00%

Debt Instrument Original Issuance Discount

25,000

Debt Instrument, Prepayment Term

'180 days

Debt Instrument, Prepayment Amount as a Percentage of Outstanding Balance

120.00%

115.00%

Debt Instrument, Convertible, Threshold Trading Days

Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger

75.00%

61.00%

Warrants Term

'5 years

Warrants and Rights Outstanding

339,864

Share Price (in Dollars per share)

$0.60

Fair Value Assumptions, Expected Term

'5 years

Fair Value Inputs, Discount Rate

1.38%

1.48%

Fair Value Assumptions, Expected Volatility Rate

149.00%

137.00%

Repayments of Convertible Debt

450,000

337,171

158,055

90,275

Payment of Prepayment Penalty

$56,195

$29,555

$11,775

Stock Issued During Period, Shares, Issued for Services (in Shares)

835,000

Note_10_Preferred_Stock_Detail

Note 10 - Preferred Stock (Details) (USD $)	Mar. 31, 2014	Mar. 13, 2014	Dec. 31, 2013	Mar. 17, 2014	Mar. 31, 2014	Mar. 13, 2014	Mar. 31, 2014
				Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]
							Maximum [Member]
Note 10 - Preferred Stock (Details) [Line Items]	'	'	'	'	'	'	'
Preferred Stock, Shares Authorized	4,993,825	5,000,000	5,000,000	'	'	6,175	'
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)	$0.00	'	$0.00	'	'	$0.00	'
Preferred Stock, Stated Value Per Share (in Dollars per share)	'	'	'	'	'	$1,000	'
Stock Issued During Period, Shares, New Issues	'	'	'	6,175	'	'	'
Convertible Preferred Stock, Shares Issued upon Conversion	'	'	'	'	2,000	'	'
Convertible Preferred Stock, Beneficial Ownership Limitation Conversion Percentage	'	'	'	'	'	'	9.99%

Note_11_Warrants_Details_Warra

Note 11 - Warrants (Details) - Warrant Activity	1 Months Ended	3 Months Ended
Note 11 - Warrants (Details) - Warrant Activity	Jul. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	52,776,792	10,625,141
Issued	'	42,151,651	'
Class A Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	1,106,627	1,106,627
Exercise Price (in Dollars per Item)	'	4	'
Expiration Date	'	'Sept, 2014	'
Class B Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	1,106,627	1,106,627
Exercise Price (in Dollars per Item)	'	8	'
Expiration Date	'	'Sept, 2014	'
Class E Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	3,576,737	3,576,737
Exercise Price (in Dollars per Item)	'	4	'
Expiration Date	'	'Apr, 2016	'
Class F Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	300,000	300,000
Exercise Price (in Dollars per Item)	'	0.35	'
Expiration Date	'	'Feb, 2018	'
Class G Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	1,503,409	1,503,409
Exercise Price (in Dollars per Item)	'	0.8	'
Expiration Date	'	'Jul, 2018	'
Class H Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	1,988,095	1,988,095
Issued	1,988,095	'	'
Exercise Price (in Dollars per Item)	0.8	0.8	'
Expiration Date	'	'Jul, 2018	'
Class I Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	1,043,646	1,043,646
Exercise Price (in Dollars per Item)	'	0.85	'
Expiration Date	'	'Sept, 2018	'
Class J Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	629,378	'
Issued	'	629,378	'
Exercise Price (in Dollars per Item)	'	0.44	'
Expiration Date	'	'Feb, 2019	'
Series A Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	25,951,421	'
Issued	'	25,951,421	'
Exercise Price (in Dollars per Item)	'	0.5	'
Expiration Date	'	'Mar, 2019	'
Series B Warrants [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Oustanding	'	15,570,852	'
Issued	'	15,570,852	'
Exercise Price (in Dollars per Item)	'	1.5	'
Expiration Date	'	'Mar, 2015	'

Note_12_Commitments_and_Contin1

Note 12 - Commitments and Contingencies (Details) (USD $)	3 Months Ended						1 Months Ended		3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Jul. 31, 2013	Nov. 27, 2012	Nov. 27, 2012	Nov. 27, 2012	Nov. 27, 2012	Nov. 27, 2012	Mar. 31, 2014
				Should Total Available Cash be Less than $100,000 [Member]	Subscription Agreement [Member]	Subscription Agreement [Member]	Subscription Agreement [Member]	Subscription Agreement [Member]	Subscription Agreement [Member]
				Subscription Agreement [Member]	On Or Before January 31, 2013 [Member]	On Or Before February 15, 2013 [Member]	On Or Before May 27, 2014 [Member]
Note 12 - Commitments and Contingencies (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)	'	'	'	'	'	'	'	4,000,000	3,600,000
Share Price (in Dollars per share)	'	'	$0.60	'	'	'	'	$0.25	'
Aggregate Sales Price for Common Stock	'	'	'	'	'	'	'	$1,000,000	'
Receivable from Shareholders or Affiliates for Issuance of Capital Stock	'	'	'	100,000	50,000	50,000	900,000	'	900,000
Minimum Installment Amount of Purchase Price	'	'	'	'	'	'	100,000	'	'
Available Cash, Threshold	'	'	'	'	'	'	'	100,000	'
Proceeds from Issuance of Common Stock	'	'	'	'	'	'	'	'	100,000
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	'	'	'	'	'	'	400,000
Operating Leases, Rent Expense, Net	$29,934	$27,474	'	'	'	'	'	'	'

Note_13_Stockbased_Compensatio2

Note 13 - Stock-based Compensation (Details) (USD $)

3 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Feb. 25, 2013

Nov. 30, 2010

Feb. 21, 2013

Feb. 25, 2013

Mar. 31, 2014

Dec. 31, 2013

Feb. 25, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Vested at Grant [Member]

Options Vesting Upon Company Completing $5.0 Million Gross Proceeds [Member]

Options Vesting Upon Company Completing $1.0 Million Gross Proceeds [Member]

Upon Events Tied To Clinical Trial Plan for DermaPACE Device [Member]

Upon Achieveing All Milestones During Initial Two Year Term and the Term is Not Extended by Company [Member]

Employee Stock Option [Member]

Stock Incentive Plan [Member]

Active Employees and Directors [Member]

Each Member of Medical Advisory Board [Member]

Members of Medical Advisory Board [Member]

Chief Executive Officer [Member]

Minimum [Member]

Maximum [Member]

Chief Executive Officer [Member]

Minimum [Member]

Chief Executive Officer [Member]

Note 13 - Stock-based Compensation (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'4 years

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'10 years

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

8,500,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

2,243,644

50,000

2,250,000

Share-Based Compensation Arrangement, By Share-Based Payment Award, Options, Cancel In Period (in Shares)

1,113,644

Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price Per Share (in Dollars per share)

$2.92

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$0.35

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

$0.22

$0.64

$0.21

Allocated Share-based Compensation Expense

$499,621

$64,000

$465,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Options Vesting (in Shares)

375,000

Cash Receipt For Option Vesting Threshold

5,000,000

1,000,000

250,000

ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod (in Shares)

375,000

750,000

Share-based Compensation

70,778

317,601

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in Dollars per share)

$1.17

$0.21

$2.92

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

28,900

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value

1,895,078

1,271,540

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value

$1,142,029

$574,181

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term

'7 years 21 days

'6 years 350 days

Note_13_Stockbased_Compensatio3

Note 13 - Stock-based Compensation (Details) - Fair Value Assumptions	3 Months Ended
	Mar. 31, 2014
Fair Value Assumptions [Abstract]	'
Weighted average expected life in years	'4 years 109 days
Weighted average risk free interest rate	0.72%
Weighted average volatility	150.00%
Forfeiture rate	0.00%
Expected dividend yield	0.00%

Note_13_Stockbased_Compensatio4

Note 13 - Stock-based Compensation (Details) - Option Activity (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Option Activity [Abstract]	'	'
Outstanding number	8,306,830	8,366,830
Outstanding weighted average exercise price per share	$1.17	$1.17
Exercised	-60,000	'
Exercised	$0.21	'
Exercisable	6,067,290	'
Exercisable	$1.48	'

Note_13_Stockbased_Compensatio5

Note 13 - Stock-based Compensation (Details) - Nonvested Options Activity (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Nonvested Options Activity [Abstract]	'	'
Outstanding number	2,239,540	3,254,092
Outstanding weighted average exercise price per share	$0.34	$0.35
Vested	-1,014,552	'
Vested	$0.35	'

Note_14_Earnings_Loss_Per_Shar1

Note 14 - Earnings (Loss) Per Share (Details)	3 Months Ended
Note 14 - Earnings (Loss) Per Share (Details)	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	73,433,622	26,726,924